LLY compared with AXSM: revenue, margins and what each company keeps, and the suppliers and customers both name

LLYELI Lilly & Co

Mkt capRevenueRevenue

AXSMAxsome Therapeutics, Inc.

Mkt capRevenueRevenue

Compare

LLYELI Lilly & Co

AXSMAxsome Therapeutics, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

LLY

3 of 4at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±5.1%▲+6.63%×1.29

Q2 FY26±6.2%▲+4.86%×0.79

Q1 FY26±5.3%▲+9.80%×1.85

Feb 4 '26±6.1%▲+10.33%×1.69

AXSM

1 of 4at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±12.7%▼−5.83%×0.46

Q2 FY26±9.0%▲+3.83%×0.42

= impliedLLY realized, solidAXSM realized, hatchedOne scale, both sides: full bar = 13%× = |realized| ÷ impliedSource: market data

Q1 FY26

±6.3%

▲+8.31%

×1.32

Feb 23 '26±7.1%▼−4.88%×0.69

LLYELI Lilly & Co

1,371.32▼−3.29%· post 1,362.32

Mkt cap$1.3TRevenue$24.4BQ3 FY26Revenue$65.2BFY25

AXSMAxsome Therapeutics, Inc.

135.90▼−0.80%· post 129.64

ClosedNov 5 '26

Mkt cap$7.2BRevenue$260MQ3 FY26Revenue$638MFY25

Compare

ClosedNov 5 '26

LLYELI Lilly & Co

AXSMAxsome Therapeutics, Inc.

1,371.32▼−3.29%post 1,362.32

Price

135.90▼−0.80%post 129.64

$1.3T

Mkt cap

$7.2B

Q3 FY26$24.4B

Revenue

$260MQ3 FY26

FY25$65.2B

Revenue

$638MFY25

LLY1,371.32▼−3.29%vsAXSM135.90▼−0.80%ClosedNov 5 '26